Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study

Fernando Corrales-Medina, Doris Quon, Miguel Escobar, Lisa Boggio, Akshat Jain, Jessica Charlet

Blood (2025) 146 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2025-3067

Published: 2025

Journal Articles

Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial

Hope Wilson, Maua Alleyne, Sanjay Ahuja, Ernest Amankwah, Aisha Bruce, Shannon Carpenter, Fernando Corrales-Medina, Craig Mullen, Arun Panigrahi, Lakshmi Srivaths, Courtney Thornburg, Anupam Verma, Gary Woods, Neil Goldenberg, Madhvi Rajpurkar

Blood (2025) 146 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2025-2680

Published: 2025

Journal Articles

Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm

Fernando Corrales-Medina, Nana Afari-Dwamena, Amanda Blair, Shannon Carpenter, Clay Cohen, Maissaa Janbain, Janice Staber, Jonathan Schwartz, Michael Recht, Tammuella Chrisentery-Singleton

Blood (2025) 146 (Supplement 1): 4472.

https://doi.org/10.1182/blood-2025-4472

Published: 2025

Journal Articles

Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience

Rachel Kronenfeld, Joicy Estevez, Sasha Inclan, Fernando Corrales-Medina

Blood (2025) 146 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2025-4381

Published: 2025

Journal Articles

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Robert Sidonio, Jr., Nathan Connell, Fernando Corrales-Medina, Caroline Malcolmson

Blood (2025) 146 (Supplement 1): 4857.

https://doi.org/10.1182/blood-2025-4857

Published: 2025

Journal Articles

Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025

Jonathan Roberts, May Chien, Sweta Gupta, Rebecca Kruse-Jarres, Erin Cockrell, Fernando Corrales-Medina, Amanda Mullery, Sarah Kreitzer, Michael Tarantino

Blood (2025) 146 (Supplement 1): 1315.

https://doi.org/10.1182/blood-2025-1315

Published: 2025

Journal Articles

Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective

Robert Sidonio, Jr., Nathan Connell, Fernando Corrales-Medina, Roberta Longo, Wei-Shi Yeh, Caroline Malcolmson

Blood (2025) 146 (Supplement 1): 1289.

https://doi.org/10.1182/blood-2025-1289

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study

Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial

Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm

Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025

Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective

Email alerts

ASH Publications

American Society of Hematology

Update search

A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study

Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial

Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm

Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025

Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only